Targeted anti-angiogenic agents, such as sunitinib, have substantially improved the outcomes of patients with renal cell carcinoma (RCC); however, intrinsic and acquired resistance are both common and ...
At close: March 3 at 6:40:46 PM EST ...
As of March 3 at 8:00:16 AM EST. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results